NY double-teams Merck in Vioxx lawsuit

Buy more stock in Merck's law firm: New York State and New York City have sued the company to recoup more than $100 million they spent on the drug, joining six other states suing on behalf of their Medicaid plans.

The suit mimics other claims against the company: that Merck intentionally concealed the bad news about Vioxx, thus inducing the state's Medicaid program to pay for a drug Merck knew could be dangerous. Merck's lawyers deny the claims, saying the company acted responsibly, and vowing--as is its habit--to vigorously defend itself.

- read the statement from NY Attorney General Andrew Cuomo
- see this article from The New York Times

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.